Astrocytoma and B-cell lymphoma development in a man with a p53 germline mutation.

We report a case with a germline mutation of the p53 gene develpoing both a non-Hodgkin's lymphoma and an astrocytoma. The astrocytoma could be cured by two operations and combined chemotherapy but 33 months after the onset of the disease, he suffered from a diffuse, large cell centroblastic malignant lymphoma of B-cell lineage. In spite of clear rearranged fragments observed with IgH and c-MYC gene probes, we could not diagnose a Burkitt's lymphoma morphologically. The malignant lymphoma was chemoresistant and the patient died of multi-organ failure. He was confirmed to have a germline mutation of the p53 gene by analysis of c-DNA from peripheral lymphocytes and loss of heterozygosity (LOH) of p53 was evident in the lymphoma. The results were suggestive of the Li-Fraumeni syndrome (LFS), a rare autosomal dominantly inherited syndrome with a germline mutation of p53 gene and diverse malignancies, but this could not be confirmed in the present case. Alternatively, a de novo mutation could have been involved.

[1]  H. Saito,et al.  Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[2]  W. Wilson,et al.  Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. , 1997, Blood.

[3]  H. Koga,et al.  Intracranial Germ Cell Tumors: Detection of p53 Gene Mutations by Single‐strand Conformation Polymorphism Analysis , 1995, Japanese journal of cancer research : Gann.

[4]  W. Feremans,et al.  CA-125 in primary mediastinal B-cell lymphoma with sclerosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[6]  H. Koeffler,et al.  p53 in hematologic malignancies. , 1994, Blood.

[7]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[8]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[9]  S. Friend,et al.  Screening patients for heterozygous p53 mutations using a functional assay in yeast , 1993, Nature genetics.

[10]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[11]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[12]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[13]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[14]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[15]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[16]  K. Hayashi,et al.  Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. , 1992, Blood.

[17]  I. Petersen,et al.  p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. , 1992, Cancer research.

[18]  E. Newcomb,et al.  p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. , 1992, Cancer research.

[19]  R. Cawthon,et al.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. , 1992, Cancer research.

[20]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[21]  J. Fraumeni,et al.  Testing for germ line p53 mutations in cancer families. , 1991, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  C. Wijmenga,et al.  DELIMITATION OF THE REGION OF COMMON ALLELIC LOSSES ON 3P IN SPORADIC RENAL-CELL CARCINOMA , 1991 .

[23]  V. Sheffield,et al.  Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Katakura,et al.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, Oncogene.

[25]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[26]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[28]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[29]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[30]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[31]  F. Li,et al.  Cancer families: human models of susceptibility to neoplasia--the Richard and Hinda Rosenthal Foundation Award lecture. , 1988, Cancer research.

[32]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.